Business Standard

Glenmark gets USFDA approval for sclerosis treatment drug

Glenmark Generics Inc has received final approval from the USFDA for Riluzole tablets in 50 mg strength

Press Trust of India  |  New Delhi 

Drug firm Pharmaceuticals today said it has received US health regulator's approval to market tablets, used in treating nervous system disorder, in the American market.

Generics Inc, the US-based subsidiary of Generics Ltd (GGL) has received final approval from the US Food and Drug Administration (USFDA) for tablets in 50 mg strength, Pharma said in a statement.



The company will commence shipping the drug immediately to the US market, it added.

is indicated for the treatment of amyotrophic lateral sclerosis. As per the Health sales data for the 12 month period ended March 2013, had garnered sales of $64 million in the US market.

The Mumbai-based firm said its current portfolio consists of 86 products authorised for distribution in the US market and 52 abbreviated new drug applications (ANDAs) are pending with the US FDA for approval.

"In addition to these internal filings, Generics Inc continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio," the company said.

A subsidiary of Pharma, focuses on developing, manufacturing, selling and the distribution of generics through wholesalers, retailers and pharmacy chains.

Shares of Pharma were trading at Rs 577.85 on the in afternoon trade, up 0.48% from its previous close.

RECOMMENDED FOR YOU

Glenmark gets USFDA approval for sclerosis treatment drug

Glenmark Generics Inc has received final approval from the USFDA for Riluzole tablets in 50 mg strength

Drug firm Glenmark Pharmaceuticals today said it has received US health regulator's approval to market Riluzole tablets, used in treating nervous system disorder, in the American market. Drug firm Pharmaceuticals today said it has received US health regulator's approval to market tablets, used in treating nervous system disorder, in the American market.

Generics Inc, the US-based subsidiary of Generics Ltd (GGL) has received final approval from the US Food and Drug Administration (USFDA) for tablets in 50 mg strength, Pharma said in a statement.

The company will commence shipping the drug immediately to the US market, it added.

is indicated for the treatment of amyotrophic lateral sclerosis. As per the Health sales data for the 12 month period ended March 2013, had garnered sales of $64 million in the US market.

The Mumbai-based firm said its current portfolio consists of 86 products authorised for distribution in the US market and 52 abbreviated new drug applications (ANDAs) are pending with the US FDA for approval.

"In addition to these internal filings, Generics Inc continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio," the company said.

A subsidiary of Pharma, focuses on developing, manufacturing, selling and the distribution of generics through wholesalers, retailers and pharmacy chains.

Shares of Pharma were trading at Rs 577.85 on the in afternoon trade, up 0.48% from its previous close.
image
Business Standard
177 22

Glenmark gets USFDA approval for sclerosis treatment drug

Glenmark Generics Inc has received final approval from the USFDA for Riluzole tablets in 50 mg strength

Drug firm Pharmaceuticals today said it has received US health regulator's approval to market tablets, used in treating nervous system disorder, in the American market.

Generics Inc, the US-based subsidiary of Generics Ltd (GGL) has received final approval from the US Food and Drug Administration (USFDA) for tablets in 50 mg strength, Pharma said in a statement.

The company will commence shipping the drug immediately to the US market, it added.

is indicated for the treatment of amyotrophic lateral sclerosis. As per the Health sales data for the 12 month period ended March 2013, had garnered sales of $64 million in the US market.

The Mumbai-based firm said its current portfolio consists of 86 products authorised for distribution in the US market and 52 abbreviated new drug applications (ANDAs) are pending with the US FDA for approval.

"In addition to these internal filings, Generics Inc continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio," the company said.

A subsidiary of Pharma, focuses on developing, manufacturing, selling and the distribution of generics through wholesalers, retailers and pharmacy chains.

Shares of Pharma were trading at Rs 577.85 on the in afternoon trade, up 0.48% from its previous close.

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard